Are you investing in biotech? IP can be a company’s best or worst asset. Here’s why.IP tends to slip into the background during the due diligence phase. Overshadowed by flashy pitch decks and promising product pipelines. IP spans both scientific depth and legal nuance, directly affecting a...
Sign up for our newsletter
